Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
307.9 USD | +0.16% | +2.66% | +7.00% |
May. 28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
May. 28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.00% | 165B | |
+42.11% | 748B | |
+34.11% | 598B | |
-6.69% | 356B | |
+18.15% | 325B | |
+3.76% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+1.67% | 166B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Transcript : Amgen Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09